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Abstract
To improve patients’ access to safe and effective biological medicines, abbreviated licensure 
pathways for biosimilar and interchangeable biological products have been established in the US, 
Europe, and other countries around the world. The US Food and Drug Administration and 
European Medicines Agency have published various guidance documents on the development and 
approval of biosimilars, which recommend a “totality-of-the-evidence” approach with a stepwise 
process to demonstrate biosimilarity. The approach relies on comprehensive comparability studies 
ranging from analytical and nonclinical studies to clinical pharmacokinetic/pharmacodynamic 
(PK/PD) and efficacy studies. A clinical efficacy study may be necessary to address residual 
uncertainty about the biosimilarity of the proposed product to the reference product and support a 
demonstration that there are no clinically meaningful differences. In this article, we propose a 
statistical strategy that takes into account the similarity evidence from analytical assessments and 
PK studies in the design and analysis of the clinical efficacy study in order to address residual 
uncertainty and enhance statistical power and precision. We assume that if the proposed biosimilar 
product and the reference product are shown to be highly similar with respect to the analytical and 
PK parameters, then they should also be similar with respect to the efficacy parameters. We show 
that the proposed methods provide correct control of the type I error and improve the power and 
precision of the efficacy study upon the standard analysis that disregards the prior evidence. We 
confirm and illustrate the theoretical results through simulation studies based on the biosimilars 
development experience of many different products.
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A biological medicine is a large molecule derived from living cells (Dranitsaris et al., 2013). 
As the patents for a large number of biological products have already expired or are due to 
expire, there is an increasing interest from both the biopharmaceutical industry and the 
regulatory agencies in the development and approval of biosimilars (Noaiseh and Moreland, 
2013; Ventola, 2013). The US Food and Drug Administration (FDA) defines a biosimilar as 
a product that is highly similar to the reference innovator product notwithstanding minor 
differences in clinically inactive components and with no clinically meaningful differences 
between the proposed biosimilar and the reference innovator product (US Food and Drug 
Administration, 2015a). Differences in cell lines and manufacturing processes make it 
impossible for biological products to be replicated exactly. Thus, the requirements to 
demonstrate similarity of biological products are different from those of demonstrating 
bioequivalence for generic small-molecule drug products that have an identical chemical 
structure.
To improve patients’ access to safe and effective biological medicines, an abbreviated 
licensure pathway for biosimilar and interchangeable biological products was established 
under section 351 (k) of the Public Health Service Act in the US. Similar legal pathways for 
approval of biosimilars were established in the European and other countries around the 
world. Various guidance documents have been published by health authorities regarding the 
development and approval of biosimilars. The FDA (2015a, 2015b, 2015c, 2016a) and 
European Medicines Agency (2014) issued guidance documents that recommend a “totality-
of-evidence” approach to assess biosimilarity with a stepwise process. The approach relies 
on comprehensive comparability studies with the reference product, progressing from 
analytical and nonclinical studies to clinical pharmacokinetic (PK) and pharmacodynamic 
(PD) studies (if there are relevant PD measures), and then to clinical efficacy studies. The 
analytical studies compare structural and functional characterization between the proposed 
biosimilar and the reference product. This serves as the foundation for a demonstration of 
biosimilarity. If there is residual uncertainty about biosimilarity after conducting analytical 
studies, animal testing, and clinical PK/PD studies, then clinical efficacy studies may be 
needed to adequately address that uncertainty, so as to support a demonstration that there are 
no clinically meaningful differences.
In light of the regulatory guidelines, it is strongly desirable to incorporate the prior 
knowledge of similarity or degree of uncertainty directly into the design and analysis of the 
clinical efficacy study. In general, the more similar the analytical and particularly the 
functional evaluations of the proposed biosimilar to the reference product are, the less 
residual uncertainty about biosimilarity there is to be addressed through the clinical studies. 
In addition, it is useful to incorporate PK similarity evidence to further reduce residual 
uncertainty and support a demonstration of no clinically meaningful differences.
In this article, we propose a statistical strategy that uses the analytical and PK similarity 
evidence from structural and functional characterization and phase 1 PK studies to reduce 
the sample size and enhance the power for a Phase 3 biosimilar efficacy study. Our 
assumption is that if the proposed biosimilar product and the reference product are highly 
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similar with respect to the analytical and phase 1 PK parameters, then they should also be 
similar with respect to the Phase 3 efficacy parameter. This strategy is in line with the FDA’s 
guidance on the stepwise process and the totality-of-the-evidence approach to establish 
similarity. No such methods have been published, although there is a large body of literature 
on bioequivalence (e.g., Chow and Liu, 2008).
The rest of this article is organized as follows. In Section 2, we describe the proposed 
methods to incorporate the prior evidence of similarity (e.g., analytical and PK similarity) to 
improve the power of equivalence test and the precision of parameter estimation for a Phase 
3 efficacy similarity study. We consider both the scenarios of a single source and multiple 
sources of prior similarity evidence. In Section 3, we conduct simulation studies to evaluate 
the proposed methods in realistic settings. Specifically, we show that the proposed methods 
preserve the type I error and enhance the power and estimation precision as opposed to 
disregarding the prior evidence when designing and analyzing the biosimilar clinical efficacy 
study. We also investigate the impact of the strength of analytical similarity on the proposed 
methods and show that combining the evidence from analytical and PK similarity can boost 
the power in the Phase 3 study. We provide some concluding remarks in Section 4.We 
relegate all theoretical details to appendices.
2. Methods
2.1. Incorporating single source of prior similarity evidence
Suppose that the parameter of interest in the prior evidence is θ, which may be a functional 
assessment for the mechanism of action, such as the primary receptor binding (particularly, 
tumor necrosis factor or TNF α binding) and antibody-dependent cellular cytotoxicity, in 
analytical studies or the logarithm of area under the curve (AUC) in the PK study. Suppose 
also that the parameter of interest in the Phase 3 trial is p, which is typically the response 
rate. Let (θT, pT) and (θR, pR) denote the values of (θ, p) for the biosimilar product to be 
tested and the reference product, respectively.
In the prior study, we test the null hypothesis
H0
(1):θT − θR < L′ or θT − θR > U′
against the alternative hypothesis
Ha
(1):L′ ≤ θT − θR ≤ U′,
where L′ ≤ 0 ≤ U′ are two specific margins. If, for example, θ is the logarithm of AUC, 
then L′ = −U′ = log(0.8). In the Phase 3 efficacy trial, we test the null hypothesis
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where L ≤ 0 ≤ U are two specific margins. Typically, U and L are symmetric around 0, i.e., 
U = −L.
If there is strong empirical evidence that θT and θR are similar, then we wish to leverage this 
information when demonstrating the similarity between pT and pR in the Phase 3 trial. There 
are several challenges in formalizing this strategy. First, the parameters θ and p have 
different scales of measurement. Secondly, it is unclear how to efficiently incorporate the 
evidence about similarity from the prior study into the design and analysis of the Phase 3 
study without making strong assumptions about the relationship between the parameters of 
the two studies. Lastly, because the prior evidence is empirical, we need to account for its 
randomness when incorporating it into the design and analysis of the Phase 3 study in order 
to control the overall type I error.
To address the first challenge, we rescale the parameters in the prior study and the Phase 3 
study by defining a relative similarity measurement (RSM), which is the ratio between the 
absolute difference of the proposed biosimilar product and the reference product and the 
range of the margins. That is, the RSMs for the prior study and the Phase 3 study are defined 
as
RSM1 =
∣ θT − θR ∣
∣ U′ − L′ ∣ , RSM3 =
∣ log pT − log pR ∣
∣ U − L ∣ ,
respectively. Because RSM is a relative difference and thus has no unit, RSM1 and RSM3 
are comparable. Furthermore, if the two products are similar within the margin, then RSM 
takes a value in [0, 1].
To address the second challenge, we impose a structural assumption on the relationship 
between RSM1 and RSM3, under which there exists a known positive constant c1 such that
i f RSM1 < c1, then RSM3 <
max { ∣ L ∣ , ∣ U ∣ }
∣ U − L ∣ . (1)
Thus, if the relative similarity in the prior study is within the bound c1, then the difference 
between the two products in the Phase 3 study should be within the margins. In other words, 
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very similar performance between the two products in the parameter of the prior study 
renders evidence that the two products perform similarly with respect to the Phase 3 
parameter. However, we do not specify any functional relationship between RSM1 and 
RSM3 but rather how the alternative hypothesis in the Phase 3 study is related to a bound for 
the relative similarity in the prior study. This structural assumption is minimal for the 
purpose of hypothesis testing. Clearly, the constant c1 governs how much information is 
borrowed from the prior study. Specifying a reasonable c1 requires some biological 
knowledge about the relationship between RSM1 and RSM3. For example, if we believe that 
RSM1 is proportional to RSM3, then for the case that L = −U, the structural assumption 
holds with c1 = RSM1/(2RSM3).
To address the last challenge, we must take into account the fact that there is some positive 
probability that the similarity evidence of RSM1 < c1 can be wrong when we construct the 
rejection region for hypothesis testing in the Phase 3 study. We propose to appropriately 
allocate the type I error as follows. Suppose that the overall type I error is set to α and that 
the null hypothesis that the two products are not similar holds for the Phase 3 study. We can 
reject the null hypothesis under one of two scenarios: (1) the empirical evidence in the prior 
study concludes that RSM1 < c1, such that the structural assumption leads to the conclusion 
that the two products are similar with respect to the Phase 3 parameter; and (2) the empirical 
evidence in the Phase 3 study indicates that the two products are similar. Thus, to control the 
overall type I error at α, we will control the error for case (1) to be under α1 (0 ≤ α1 ≤ α) 
while controlling the error for case (2) to be under (α − α1). We provide a formal derivation 
and justification in Appendix A.
Note that, in the design stage, α1 in the type I error spending needs to be specified before the 
Phase 3 study. We propose to search for the optimal α1 such that the power under the 
alternative hypothesis in the Phase 3 study is maximized at the design stage. We show in 
Appendix B how to find this optimal α1. After the Phase 3 study is completed, the ideas for 
using the structural assumption and error spending can be used to refine the confidence 
interval in the Phase 3 study at the analysis stage, where the error of using the prior evidence 
can be either fixed beforehand or determined in a data-adaptive manner. The details are 
provided in Appendix C.
2.2. Incorporating multiple sources of prior similarity evidence
We now extend the proposed methods to combine multiple sources of similarity evidence 
from, for example, analytical assessments and phase 1 PK studies. Suppose that there are K 
sources of similarity evidence. For k = 1, …, K, the parameters for the proposed biosimilar 
product and the reference product in the kth source of evidence are denoted by θTk and θRk, 
respectively, and the corresponding margins are denoted by Lk′  and Uk′ . To combine the K 








Zeng et al. Page 5













where w1, …, wK are pre-specified weights such that ∑k = 1
K wk = 1. With this definition of 





wkθTk /(Uk′ − Lk′ ), θR = ∑
k = 1
K
wkθRk /(Uk′ − Lk′ )
and set L′ = ≤0.5 and U′ = 0.5, then RSM1 = |θT − θR|/|U′ − L′|. Thus, the design and 
analysis procedures described in section “Incorporating single source of prior similarity 
evidence” can be applied to multiple sources of prior evidence by treating θT and θR as the 
single parameter for the prior evidence. The implementation requires knowledge of the 
covariances between the estimators of (θT1, …, θTK)T and (θR1, …, θRK)T if the parameters 
are estimated from the same study. If the two sets of parameters pertain to analytical 
assessments and the PK study, then the covariance is zero.
The weights wk reflect the importance of each source of prior evidence. If one of the wk is 1 
and the rest are 0, then we recover the set-up of one source of similarity evidence described 
in section “Incorporating single source of prior similarity evidence”. The weights should be 
chosen on the basis of scientific knowledge, such as the extent of similarity in primary and 
secondary functions, together with overall structural/functional similarity. As functional tests 
are considered to be highly correlated with efficacy, more weights should be given to 
analytical similarity results than to PK similarity results. It is desirable to explore a range of 
values for the weights.
3 Numerical studies
3.1 Type I error and power
We conducted simulation studies to examine the performance of the proposed methods in 
practical situations. The first simulation study was designed to assess the type I error when 
the Phase 3 null hypothesis holds, and the second simulation study was designed to assess 
the power gain of the proposed method over the standard method that does not use the prior 
information. In both simulation studies, we simulated n1 = 50 subjects from each treatment 
arm in the prior study and n3 = 300 from each treatment arm in the Phase 3 study. We varied 
the threshold c1 from 0.1 to 0.8 in a grid size 0.1. For each combination of simulation 
parameters, we set the number of replicates to 10,000.
In the first simulation study, we set the parameter value for the reference product in the prior 
study as θR = 5 and set the two margins as L′ = −U′ = log(0.8). In addition, we set the 
response rates for the two products in Phase 3 as pR = 0.4 and pT = 0.75pR. We let the two 
margins for Phase 3 be L = −U = log(0.75), such that the Phase 3 null hypothesis holds. 
Since the structural assumption must hold, the parameter value for the proposed biosimilar 
product, θT, should satisfy RSM1 ≥ c1. We particularly chose RSM1 = 1.25c1 by setting θT = 
1.25c1(U′ − L′) + θR. Thus, we generated n1 measurements from N(θR, 0.112) for the 
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reference product and from N(θT, 0.12) for the proposed biosimilar product. In Phase 3, we 
generated n3 binary responses from Bernoulli(pR) for the reference product and from 
Bernoulli(pT) for the proposed biosimilar product.
In the second simulation study, we adopted the same simulation set-up but let pT = pR = 0.4 
and θT be 0.75c1(U′ − L′) + θR. The latter condition guarantees that the structural 
assumption is satisfied under the alternative hypothesis Ha
(3). With n3 = 300, the power of the 
Phase 3 trial is 80% at α = 0.05.
For each simulated data set, we applied the method described in Appendix A to obtain the 
rejection region at the significance level of α = 5%. We set α1/α to 0, 0.2, or 0.4. Clearly, α1 
= 0 is equivalent to using the Phase 3 data only. We also applied the method described in 
Appendix B with 1 million Monte Carlo samples to obtain the optimal type I error for using 
the prior evidence, α1
opt. Finally, we used the method described in Appendix C to construct 
the 90% confidence intervals for log(pT/pR) corresponding to different choices of α1.
Figure 1 displays the results from the first simulation study, including the empirical type I 
error at the 5% significance level, the coverage probability of the 90% confidence interval, 
and the relative width of the 90% confidence interval based on different α1 over that of using 
the Phase 3 data only. Clearly, the type I error rates for all the methods are below the 
nominal significance level for all values of c1, and the coverage probabilities of the 
confidence intervals are all above the nominal level of 90%. Using a pre-specified value of 
α1 tends to yield conservative type I error and wider confidence intervals. By contrast, the 
proposed method based on the optimal choice of α1 provides accurate control of the type I 
error and the tightest confidence intervals. For the particular parameter set-up in this 
simulation, the method based on αopt performs very similarly to the method using the Phase 
3 data only because the value of αopt turns out to be close to 0. This is due to the fact that pT 
= pR, such that the Phase 3 data almost possess sufficient power to reject the null hypothesis.
Figure 2 displays the results from the second simulation study. The proposed method based 
on αopt has the highest power and the shortest confidence intervals for all choices of c1. The 
power increases and the confidence interval becomes narrower as c1 increases. Thus, using 
the prior evidence through the structural assumption in an optimal way leads to higher power 
and more accurate estimation for the Phase 3 study.
3.2 Impact of the strength of analytical similarity evidence
It is worthwhile to investigate how the strength of the prior evidence may impact the Phase 3 
study in our approach. The strength mostly depends on the extent of similarity in the prior 
study. Thus, we conducted a simulation study to evaluate the power and estimation results 
for the Phase 3 study after incorporating the evidence from analytical assessments, where the 
extent of similarity varies in terms of the variability or the difference pertaining to a 
functional test (e.g., TNFα binding affinity) between the proposed biosimilar product and 
the reference product. Specifically, we generated 10 measurements from N(1.08 + δ, σ2) for 
the reference product and 10 measurements from N(1.08, σ2) for the proposed biosimilar 
product. Clearly, the larger the value of δ or σ is, the weaker the evidence is. We let L′ = −U
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′ = −0.1497. For Phase 3, we set pT = pR = 0.85 and set the margins for pT − pR as L = −U = 
−0.15. We set the type I error at 0.05 and restricted α1 to be less than 0.01 so as to avoid the 
situation in which the analytical evidence is sufficient to conclude the success of Phase 3. 
We first fixed δ = 0.04 and varied σ in order to assess the impact of the variability of the 
measurements. We then fixed σ = 0.09 and varied δ in order to assess the impact of the 
actual product difference in analytical assessments.
If the prior evidence is not used, then the sample size of 98 per arm is required to achieve the 
power of 80%. Figure 3(a) displays the ratio of the sample size for using the analytical 
evidence to the sample size for not using the prior evidence (i.e., 98) under five different 
values of σ. To determine the sample size, we searched over a wide range of sample sizes to 
obtain the smallest sample size such that the power calculated in Appendix B was at least 
80%. Figure 3(b) displays the power of the proposed method for analyzing the Phase 3 data. 
The strength of the analytical evidence, characterized by σ, has strong impact on the results. 
For example, under c1 = 0.4, the value of σ = 0.07 reduces the sample size from 98 to about 
69, and even with the reduced sample size, the average power is increased from 80% to 87%. 
Figure 3(c) and (d) show the ratio of the sample sizes and the power when the difference 
between the two products, δ, changes. The conclusion is similar: the smaller the value of δ is 
(i.e., the stronger the analytical similarity is), the more gain we achieve for both the design 
and the analysis of the Phase 3 study.
3.3 Impact of analytical and PK similarity evidence
In this simulation study, we combined two sources of similarity evidence, one from 
analytical assessments and one from a phase 1 PK study, and evaluated their impact on the 
sample size and power of a future Phase 3 efficacy study. For the first source, we generated 
comparative measurements from N(1.08, 0.0892) for the proposed biosimilar product and 
from N(1.12, 0.12) for the reference product based on the established functional similarity 
(US Food and Drug Administration, 2016b). The corresponding margins were 
L1′ = − U1′ = − 0.1497. The parameter in the second source is the logarithm of the AUC in a 
PK study (Yoo et al., 2017). We generated 45 observation on the logarithm of the AUC for 
the reference product from N(8.9099, 0.32) and 96 observations for the proposed biosimilar 
product from N(8.9668, 0.32), and we set L2′ = − U2′ = log (0.8). For the Phase 3 study, we 
set pT = pR = 0.85, and the margins of their equivalence were L = −U = −0.15. We used the 
proposed method to combine these two sources of similarity evidence. The two sources were 
derived from independent studies, so the parameter estimators are uncorrelated. We varied 
the weight for the analytic evidence, i.e., w1, from 1 to 0, in order to examine the impact of 
the contribution from each evidence. Again, we set α1 to be at most 0.01. As shown in 
Figure 4, adding PK similarity evidence (i.e., setting w1 < 1) further reduces the sample size 
and increases the study power as compared to using analytical similarity evidence alone (i.e., 
w1 = 1). When c1 = 0.4 and the desired power is 0.85, the candidate values of w1 are 0.25, 
0.5, and 0.75. Since the analytic similarity is deemed the most relevant to the clinical 
outcome, the best choice of the weight would be w1 = 0.75.
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We have developed a simple and effective strategy to reduce the sample size and improve the 
power and estimation for the Phase 3 efficacy trial of biosimilars by leveraging the prior 
similarity evidence from multiple sources such as analytical assessments and PK studies. 
Our approach hinges on the structural assumption, under which strong evidence for 
similarity in the parameters of prior studies implies similarity in the Phase 3 parameter. This 
assumption is a qualitative rather than a functional relationship between the two similarity 
measures.
From a Bayesian point of view, the structural assumption can be regarded as a prior 
distribution for the two similarity measures. The corresponding prior is qualitative. We may 
use a more continuous prior distribution by assuming that RSM3/RSM1 − 1~N(0, σ2), which 
is equivalent to a ridge penalty for (RSM3/RSM1 − 1)2. The hyperparameter σ2 plays the 
role of c1 to govern how much prior similarity evidence is used to reinforce the Phase 3 trial. 
The continuous prior/penalty is computationally easier to handle than the discrete prior. 
However, it is not desirable to constrain the parameters when RSM3 is far from RSM1.
The choice of c1 is a critical aspect of the proposed methods. We recommend to determine 
c1 using the evidence on related products with approved indications. For example, for an 
infliximab biosimilar product approved by the FDA in 2016, the analytical similarity (as 
measured by TNFα binding affinity) yields the difference between the reference and test 
products as 2.59% with the margins of −7.04% and 7.04%, and the clinical similarity as 
measured by ACR20 yields the difference of 2% with the margins of −15% and 15% (Yoo et 
al., 2017). For a biosimilar later approved by the FDA for similar indications, the analytical 
similarity is −3.6% with the margins of −14.97% and 14.97%, and the clinical similarity is 
−0.4% with the margins of −12% and 12% (US Food and Drug Administration, 2016b). 
Thus, the ratio RSM1/RSM3 is estimated at 2.76 for the first study and at 7.46 for the second 
study. This empirical evidence suggests that c1, which is chosen as half of this ratio to satisfy 
the structural assumption, can be as large as 1.3. In addition to empirical evidence, it is 
worthwhile to conduct sensitivity analysis to examine the power over a range of values for c1 
when designing a new Phase 3 study and when analyzing data after the study is completed.
If the prespecified value of c1 is not small, the prior evidence may be strong enough to reject 
the Phase 3 null hypothesis, such that there is no need to run the Phase 3 study. To reduce 
the likelihood of this scenario, we may, as in the numerical studies, restrict α1 to be within a 
certain threshold, such that we will use only the prior evidence when RSM1 < c1 is 
supported by prior studies with very high probability. The optimal error spending may be 
different between the design stage and the analysis stage, as the former aims to maximize 
power whereas the latter aims to construct the narrowest confidence interval that depends on 
the empirical data in the Phase 3 study. This difference was observed in our numerical 
studies.
We have assumed that the endpoint for the Phase 3 efficacy study is a binary response. We 
can easily extend our methods to a time-to-event endpoint. The null hypothesis will then 
pertain to the hazard ratio instead of the ratio of the two response rates.
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The FDA recommended a tier approach to statistical analysis based on a critically risk 
ranking as described by Tsong et al. (2017). For the attributes with the highest risk to 
clinical outcomes (Tier 1), which include assays that evaluate clinically relevant mechanisms 
of action of the product, a demonstration of statistical equivalence is required. Specifically, 
the equivalence is demonstrated if the confidence interval for the difference in the mean 
between the proposed biosimilar product and the reference product is fully contained within 
the equivalence acceptance region. For the quality attributes with lower risk ranking (Tier 2), 
the similarity is assessed by comparing the individual results of the proposed biosimilar 
product with a quality range based on the mean and standard deviation of the reference 
product dataset. Finally, for the quality attributes with the lowest risk ranking and those that 
do not deliver quantitative results (Tier 3), the similarity is assessed qualitatively by using 
raw data and graphical comparisons.
The methods proposed in this article can be applied directly to the quantitative similarity 
evidence from Tier 1 quality attributes, as illustrated in sections “Impact of the strength of 
analytical similarity evidence” and “Impact of analytical and PK similarity evidence”. The 
proposed methods can also be applied to the similarity evidence from Tier 2 attributes by 
treating the quality range as the margin. However, the requirement to show similarity for 
Tier 2 quality attributes is different from the rigorous bio-equivalence test described in this 
article, so the use of the proposed methods to incorporate the similarity evidence from Tier 2 
attributes may require further consideration. For Tier 3 quality attributes whose similarity 
evidence is qualitative, the proposed methods cannot be directly applied. Since Tier 2 and 
Tier 3 quality attributes have low or no risk to patients, the proposed methods remain a 
viable approach to efficiently leverage the prior analytical similarity information from Tier 1 
attributes for the design and analysis of a biosimilar clinical study.
In the proposed methods, weights are introduced to combine multiple sources of similarity 
evidence. As with any weighted statistical methods, the choice of the weights is challenging, 
and the weights should reflect the importance of each source of the prior evidence. Since 
functional attributes are most relevant to clinical outcomes, we recommend that more 
weights be given to the functional similarity evidence, especially the Tier 1 functional 
attributes. In addition, the weights should be reference-drug specific and be determined 
according to the scientific knowledge about the relevance of the prior evidence (from 
structural, functional, and PK studies) on the clinical outcomes for the reference product. 
Ultimately, the acceptable values for weights become a negotiating point between the 
sponsor and regulatory agencies, and it will be up to regulatory agencies to decide whether 
the same approach to design a clinical similarity study should be implemented by different 
biosimilar applicants.
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Appendix A. Rejection Region for Hypothesis Testing in the Phase 3 Study
First, we construct a rejection region based on the prior evidence data such that the type I 
error to reject the null hypothesis H0
∗: RSM1 ≥ c1 is controlled at α1. Specifically, let θ̂T and 
θ̂R denote the estimators of θT and θR, and let σT
2  and σR
2  denote the corresponding variance 
estimators. Write δ1 = θT − θR and δ̂1 = θ̂T − θ̂R. Then δ̂1 is approximately normal with 




P δ1 − v1z1 − α1/2
≤ δ1 ≤ δ1 + v1z1 − α1/2
= 1 − α1,
where zp is the 100p th percentile of the standard normal distribution. It follows that
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P( ∣ δ1 ∣ ≤ Zα1
) ≥ 1 − α1,
where
Zα1
= max δ1 − v1z1 − α1/2 ∣, ∣ δ1 + v1z1 − α1/2 . (2)
That is, [0, Ẑα1/|U′ − L′|] is a (1 − α1)100% confidence interval for RSM1. Hence, we 
reject H0
∗ when c1 is within this interval, i.e., Ẑα1 ≤ c1|U′ ≤ L′|. This rejection region has the 
type I error of α1.
Second, we construct a rejection region based on the Phase 3 data such that the type I error 
is controlled at α3. This can be achieved by using the standard equivalence test. Define δ3 = 
log pT/pR and δ̂3 = log p̂T/p̂R. We estimate the variance of δ̂3 by 
v3
2 = pT(1 − pT)/(nT pT
2 ) + pR(1 − pR)/(nRpR
2 ), where nT and nR are the sample sizes for the 
proposed biosimilar product and the reference product, respectively, in the Phase 3 study. 
Clearly, δ̂3 is approximately normal with mean δ3 and variance v3
2. Thus, a (1 − 2α3)100% 
confidence interval for δ3 is[L̂α3, Ûα3], where
Lα3
= δ3 − v3z1 − α3
, Uα3
= δ3 + v3z1 − α3
.
Hence, we reject H0
(3) if [L̂α3, Ûα3] is contained in [L,U]. This rejection region controls the 
type I error at the level of α3. Combining the above two regions and setting α3 = α − α1, we 
obtain the overall rejection rule for H0
(3)
Aα1
= I([Lα − α1
, Uα − α1
] ⊂ [L, U] or Zα1
≤ c1 ∣ U′ − L′ ∣) .
Suppose that the null hypothesis H0
(3) holds. Then the structural assumption implies that the 
null hypothesis H0
∗ also holds. Thus,
P(Aα1
= 1) ≤ P([Lα − α1
, Uα − α1
] ⊂ [L, U]) + P(Zα1
≤ c1 ∣ U′ − L′ ∣ )
≤ (α − α1) + α1 = α .
In other words, the overall probability of rejection is no larger than α under H0
(3).
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Appendix B. Optimal Type I Error Spending
Under the alternative hypothesis Ha
(3), the probability of no rejection is
P(L > Lα − α1
or Uα − α1
> U)P(Zα1








− zα − α1









c1 ∣ U′ − L′ ∣
v1
,
where N(0, 1) denotes a standard normal random variable, Φ is the standard-normal 
distribution function, and ν1 and ν3 are obtained from ν̂1 and ν̂3, respectively, by replacing 
the parameter estimators with the true parameter values. Denote the right side of the above 
inequality by G(α1). We then search over α1 ∈ [0, α] such that the power 1 − G(α1) is 
maximized. Note that 1 − G(0) is the power without using the prior evidence.
We construct the optimal rejection region as follows:
Step 1. We obtain θT̂, θ̂R and (δ̂1, ν̂1) using the prior study data.
Step 2. We obtain δ3 = log pT/pR and ν3 under Ha
(3).
Step 3. We search over a grid of α1 in [0, α] to evaluate G(α1), where δ1 and ν1 are 
replaced by δ̂1 and ν1̂, respectively. In particular, the probabilities in G(α1) are 
calculated by Monte Carlo simulation.
Step 4. We determine α1





Appendix C. Refined Confidence Region in the Phase 3 Study Using the 
Prior Evidence
The idea of using the prior information for hypothesis testing in the Phase 3 study can be 
extended to obtain a narrower confidence interval for δ3. To construct a (1 − 2α)100% 
confidence interval (corresponding to the hypothesis testing for equivalence with the type I 
error α), we split α into α1 and (α − α1). Using the prior evidence, we calculate Ẑα1 as 
before such that P(|δ1| ≤ Ẑα1) ≥ 1 − α1. Thus, if RSM1 ≥ c1, then
P(Zα1
≤ c1 ∣ U′ − L′ ∣ ) ≤ P(Zα1
≤ ∣ δ1 ∣ ) ≤ α1 .
Using the Phase 3 data, we construct a (1 − 2α + 2α1)100% confidence interval for δ3 as 
(L̂α−α1, Ûα−α1), such that
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P(δ3 ≤ Lα − α1
) ≤ α − α1, (δ3 ≥ Uα − α1
) ≤ α − α1 .
By combining the above two confidence intervals, we obtain
[L f , U f ] =
[Lα − α1
, Uα − α1
] i f Zα1
> c1 ∣ U − L′ ∣
[Lα − α1
∨ L, Uα − α1
∧ U] otherwise
where a ∨ b = max (a, b), and a ∧ b = min(a, b). If α1 = 0, then [L̂f, Ûf] reduces to [L̂α, Ûα], 
which is the confidence interval based on the Phase 3 data only.
To see why the proposed confidence interval has the correct coverage, we note that
P(δ3 ≤ L f ) = P(δ3 ≤ Lα − α1
, Zα1
> c1 ∣ U′ − L′ ∣ ) + P(δ3 ≤ Lα − α1
∨ L, Zα1
≤ c1 ∣ U′ − L′ ∣ )
≤ (α − α1)P(Zα1
> c1 ∣ U′ − L′ ∣ ) + P(δ3 ≤ Lα − α1
or δ3 ≤ L)P(Zα1
≤ c1 ∣ U′ − L′ ∣ ) .
We consider the second term on the right side. If δ3 > L, then this probability is less than
P(δ3 ≤ Lα − α1
)P(Zα1
≤ c1 ∣ U′ − L′ ∣ ) ≤ (α − α1)P(Zα1
≤ c1 ∣ U′ − L′ ∣ ) .
If δ3 ≤ L, then since the structural assumption implies that RSM1 > c1 and thus |δ1| > Ẑα1, 
this probability is less than
P(Zα1
≤ c1 ∣ U′ − L′ ∣ ) ≤ P(Zα1
≤ ∣ δ1 ∣ ) ≤ α1 .
In either case,
P(δ3 ≤ L f ) ≤ α .
Likewise, we conclude that P(δ3 ≥ Ûf) ≤ α. That is, [L̂f, Ûf] is a valid (1 − 2α)-confidence 
interval for δ3. We can search for the optimal α1 such that the resulting confidence interval 
has the shortest length.
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If we use the confidence interval to perform the hypothesis test by rejecting H0
(3) when [L̂f, 
Ûf] ⊂ [L,U], then we reject H0
(3) when either Ẑα1 ≤ c1|U′ − L′| or [Lα̂−α1, Ûα−α1] ⊂ [L,U]. 
This is exactly the rejection region described in Appendix A.
Remark 2
When analyzing the Phase 3 data, we may adjust for covariates through a log-linear 
regression model:
log p = δ3G + ξ
TX,
where G is the indicator for the proposed biosimilar product versus the reference product, 
and X is the set of covariates including the unit component.
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Simulation results under the null hypothesis: (a) type I error of the equivalence test; (b) 
coverage probability of the 90% confidence interval; and (c) ratio of the widths of the 
confidence intervals with versus without the prior evidence. The solid, dashed, dotted, and 
dot-dashed curves pertain to α1
opt, α1 = 0, α1 = 0.2α, and α1 = 0.4α, respectively. The solid 
and dashed curves are indistinguishable.
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Simulation results under the alternative hypothesis: (a) power of the equivalence test; (b) 
coverage probability of the 90% confidence interval; and (c) ratio of the widths of the 
confidence intervals with versus without the prior evidence. The solid, dashed, dotted, and 
dot-dashed curves pertain to α1
opt, α1 = 0, α1 = 0.2α, and α1 = 0.4α, respectively.
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Simulation results for using the analytical assessment evidence in both designing and 
analyzing the Phase 3 study: (a) and (c) show the ratio of the sample sizes in the Phase 3 
study to achieve the power of 80% when the prior evidence is used versus when it is not 
used; and (b) and (d) show the power of the proposed equivalence test in analyzing the Phase 
3 data.
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Simulation results for combining both analytical and PK similarity evidence: (a) ratio of the 
sample sizes in the Phase 3 study to achieve the power of 80% when the prior evidence is 
used versus when it is not used; and (b) power of the proposed equivalence test in analyzing 
the Phase 3 data.
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